Synairgen Share Discussion Threads

[toffeeman] 01/4/2020 10:06

Licht has sold some so far

[fidra] 01/4/2020 10:04

Re post 1848 all the buys at the time have now come through.for some reason they only showed the sell.......

[wetdream] 01/4/2020 10:03

Wonder if Licht & Griffiths will hang on for the longer term?

[2nell] 01/4/2020 10:02

Now buying them back--

[dealer55] 01/4/2020 09:59

Dumping or buying ?

[bmnsa] 01/4/2020 09:56

Idiot.
I'm long 'and' short but my core holding stays,as many are doing.

[2nell] 01/4/2020 09:53

Somebody has been dumping 10k of shares all morning!!

[dealer55] 01/4/2020 09:48

Bmnsa so why are you here then. Why care. Follow the money and sell out. Of but you don’t hold do you. Weasel.

[fatnacker] 01/4/2020 09:47

healthy consolidation.

[nobbygnome] 01/4/2020 09:43

The trades at 61.375 and 61.4 are buys...

[bmnsa] 01/4/2020 09:43

Who really knows!!
Cash is being taken out and staying out imo.

[hazl] 01/4/2020 09:34

A sinking Dow can lead to more interest in the shares like this I find .
Just the opposite.
It's like where else is there to go,sort of reaction.

IMO

[nobbygnome] 01/4/2020 09:29

Hopefully we will get the answer to the no of patients later today. My guru is weaving his magic...

[makendon] 01/4/2020 09:25

Sorry, this looks to have been posted on their website yesterday...sorry if I’m repeating



UK biotech Synairgen has started dosing patients in its phase 2 trial of SNG001, an inhaled formulation of interferon beta-1a that aims to treat coronavirus infections.

The drug is already widely used in an injectable form for multiple sclerosis, and Synairgen has already tested its inhaled version in clinical trials involving more than 200 asthma patients with a cold or flu infection, showing improvements in lung function.

The Southampton-based company says the first patient with COVID-19 has now been given SNG001 at the University Hospital Southampton NHS Foundation Trust, with another six trial sites due to start dosing additional subjects in the next few days.

Last week, Synairgen raised £14 million (around $17 million) in an oversubscribed funding round to pay for the SNG001 trial, shortly after getting a green light for the study from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA).

Interferon beta orchestrates the body’s response to a viral infection, and there is some evidence to suggest that people who get dangerously sick after being infected with SARS-CoV-2 – the virus that causes COVID-19 – have lower than usual levels of interferon beta in the lungs.

Synairgen also says viruses – including coronaviruses such as SARS-CoV-2 and MERS-CoV – have evolved mechanisms which suppress the production of interferon beta in the body, helping them evade the immune system.

If its hypothesis is correct, giving SNG001 via a nebuliser into the lungs could reduce viral replication and cell damage, hastening patients’ recovery from the infection. That’s backed up by animal data showing reduced lung viral load and lung pathology in a swine flu model of viral pneumonia.

The trial is being led by Professor Tom Wilkinson, a consultant in respiratory medicine at University Hospital Southampton and professor of respiratory medicine at the University of Southampton.

Investigators aim to enroll 100 patients in the pilot phase, expected to last about two months, and expand the study population if initial results are encouraging. The hope is that the drug could be made swiftly available, for example under emergency use measures, if SNG001 proves to be effective.

There is of course still a long way to go before that point however, and questions remain about how quickly production could be scaled up to meet demand as confirmed cases of COVID-19 hit almost 800,000 worldwide, including more than 22,100 in the UK.

“A successful outcome from this trial in COVID-19 patients would be a very important step towards a major breakthrough in the fight against this coronavirus pandemic,” said Richard Marsden, Synairgen’s chief executive.

The company is also close to completing a 120-patient phase 2 trial of SNG001 in chronic obstructive pulmonary disease (COPD) patients with viral infections, with 109 patients enrolled, but further recruitment has been put on hold during the pandemic to minimise the chance of vulnerable patients being exposed to COVID-19.

The start of the trial was welcomed by BioIndustry Association CEO Steve Bates, who said: “The UK life science ecosystem is stepping up across the piece on coronavirus.”

He went on: “This shows the speed at which our ecosystem can move; linking SMEs, the established UK clinical trials infrastructure of the NHS and an enabling regulator in the UK’s MHRA.”

“The sector is also working flat out on innovative emergent ventilator capacity, novel vaccine scale-up capacity, new ways to support NHS patients at home with digital products and investigating antibody technology for therapeutic use.”

[bmnsa] 01/4/2020 09:22

I think any rises will be sold into today.

edit- a sinking Dow doesn't help.

[makendon] 01/4/2020 09:09

Looks like the majority of large sell trades filtering through are from opening bell...

[hazl] 01/4/2020 09:08

Expect it to pick up.

Some Times readers might be waiting their time.

[hazl] 01/4/2020 09:07

If the general market is down the covid related shares pick up it seems to me.

[hazl] 01/4/2020 09:06

Yes, I had a
phone call from my nephew,whose family had all had symptoms and it was his first night out of quarantine!
If they had it ....little girl was sent home from school with a cough....then they had mildly thankfully.

[bmnsa] 01/4/2020 08:58

The night sky was incredible last night:))I take my daily exercise then.

[sidny1] 01/4/2020 08:57

Is it just me or is the advfn not corresponding correctly with actual sp?

[makendon] 01/4/2020 08:49

Hold on though, the despicable MMs haven’t finished yet, there will be another shake coming soon...

[nobbygnome] 01/4/2020 08:48

Yes very strong this morning. I must admit I was expecting a sell off.

[festario] 01/4/2020 08:48

It's the only thing blue on my entire monitor!